Lördag 21 December | 17:56:36 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-08-19 14:30 Kvartalsrapport 2025-Q2
2025-05-18 14:30 Kvartalsrapport 2025-Q1
2025-02-14 N/A Årsstämma
2025-02-14 15:00 Bokslutskommuniké 2024
2024-11-29 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-31 - Årsstämma
2024-05-22 - Kvartalsrapport 2024-Q1
2024-05-17 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2024-02-14 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-26 - Årsstämma
2023-05-26 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-10-11 - Extra Bolagsstämma 2022
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-22 - X-dag ordinarie utdelning EEVIA 0.00 SEK
2022-06-21 - Årsstämma
2022-05-27 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-09 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-06-22 - Årsstämma
2021-05-18 - Kvartalsrapport 2021-Q1

Beskrivning

LandFinland
ListaSpotlight
SektorHandel & varor
IndustriDetaljhandel
Eevia Health är verksamma inom life science. Bolaget erbjuder produktionsprotokoll och procedurer för att leverera ekologiska produkter till internationella kunder. Produkterna säljs till företagskunder och inkluderar ingredienser till producenter av kosttillskott, livsmedel och kosmetika på global basis. Produkterna innefattar exempelvis blåbär, chaga-svamp och tallbark. Eevia Health grundades 2017 och har sitt huvudkontor i Seinäjoki, Finland.
2024-10-30 08:15:00

A press release on October 7 (Correction on November 14) notified the shareholders of Eevia Health Plc ("Eevia" or "The Company") of an Extraordinary General Meeting to be held on November 4, 2024. Proposed changes to the Board composition were presented, except for one proposed member, who was described without name. The Marketplace has vetted the final candidate, and we can announce that this is Dr. Diane Clayton, a merited industry professional with a solid scientific track record.

Dr. Diane Clayton is an experienced and accomplished nutrition, food science, and applied biochemistry expert with four decades of research, product development, teaching, and commercial experience. Diane has occupied global leadership positions in large corporations and start-ups. She has considerable expertise in formulating nutritional strategies to promote health and prevent lifestyle-related chronic condition, with expertise in areas such as obesity, weight management, gut health, and sports nutrition.
 

Dr. Clayton earned her B.Sc. (Hons.) degree in Biochemistry from the University of Bath, U.K., and her Doctoral degree in Physiological Chemistry from the University of Fribourg, Switzerland. She is also an accredited U.K. Nutritionist, a Complementary Medicine practitioner in Switzerland, and a certified Functional Foods Scientist (U.S.). She has played an active role in health promotion in local community settings and promotes nutrition and lifestyle approaches to tackle obesity and related chronic conditions. She also has significant teaching experience at the undergraduate and postgraduate levels. Diane maintains extensive contacts with the international academic and business world and is an active member of numerous health-focused scientific societies.

"We are extremely excited to welcome Dr. Clayton to the Board of Directors of Eevia Health. She has already advised us on gut health strategies, and we have experienced the wealth of knowledge and personal network she has that is directly relevant to the business plans we have for Eevia," says Stein Ulve, Eevia's CEO.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.comorinvestor@eeviahealth.com

Telephone: +358400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga mushroom, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA (https://spotlightstockmarket.com/en/companies/irabout?InstrumentId=XSAT000085FD).

To learn more, please visit www.eeviahealth.comor follow Eevia Health on LinkedIn@EeviaHealth.